# Table of Contents

<table>
<thead>
<tr>
<th>Section</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Header</td>
<td>1</td>
</tr>
<tr>
<td>Abstract</td>
<td>1</td>
</tr>
<tr>
<td>Plain Language Summary</td>
<td>2</td>
</tr>
<tr>
<td>Summary of Findings for the Main Comparison</td>
<td>3</td>
</tr>
<tr>
<td>Background</td>
<td>5</td>
</tr>
<tr>
<td>Objectives</td>
<td>5</td>
</tr>
<tr>
<td>Methods</td>
<td>6</td>
</tr>
<tr>
<td>Results</td>
<td>7</td>
</tr>
<tr>
<td>Figure 1</td>
<td>8</td>
</tr>
<tr>
<td>Figure 2</td>
<td>9</td>
</tr>
<tr>
<td>Discussion</td>
<td>9</td>
</tr>
<tr>
<td>Authors' Conclusions</td>
<td>10</td>
</tr>
<tr>
<td>Acknowledgements</td>
<td>10</td>
</tr>
<tr>
<td>References</td>
<td>10</td>
</tr>
<tr>
<td>Characteristics of Studies</td>
<td>12</td>
</tr>
<tr>
<td>Data and Analyses</td>
<td>18</td>
</tr>
<tr>
<td>Analysis 1.1. Comparison 1 Surgical failure, Outcome 1 IOP &gt; 21 mmHg 12 months or more after surgery.</td>
<td>19</td>
</tr>
<tr>
<td>Analysis 2.1. Comparison 2 Intraocular pressure (IOP), Outcome 1 Mean IOP 12 months or more after surgery.</td>
<td>20</td>
</tr>
<tr>
<td>Analysis 3.1. Comparison 3 Adverse effects, Outcome 1 Cataract.</td>
<td>20</td>
</tr>
<tr>
<td>Analysis 3.2. Comparison 3 Adverse effects, Outcome 2 Hypotony.</td>
<td>21</td>
</tr>
<tr>
<td>Analysis 3.3. Comparison 3 Adverse effects, Outcome 3 Bleb leak.</td>
<td>21</td>
</tr>
<tr>
<td>Additional Tables</td>
<td>21</td>
</tr>
<tr>
<td>Appendices</td>
<td>22</td>
</tr>
<tr>
<td>History</td>
<td>24</td>
</tr>
<tr>
<td>Contributions of Authors</td>
<td>24</td>
</tr>
<tr>
<td>Declarations of Interest</td>
<td>24</td>
</tr>
<tr>
<td>Sources of Support</td>
<td>24</td>
</tr>
<tr>
<td>Differences between Protocol and Review</td>
<td>25</td>
</tr>
<tr>
<td>Index Terms</td>
<td>25</td>
</tr>
</tbody>
</table>
Beta radiation for glaucoma surgery

James F Kirwan¹, Christina Rennie², Jennifer R Evans³

¹Department of Ophthalmology, Queen Alexandra Hospital, Portsmouth, UK. ²Department of Ophthalmology, Southampton Eye Unit, Southampton General Hospital, Southampton, UK. ³Cochrane Eyes and Vision Group, ICEH, London School of Hygiene & Tropical Medicine, London, UK

Contact address: James F Kirwan, Department of Ophthalmology, Queen Alexandra Hospital, Cosham, Portsmouth, Hampshire, PO6 3LY, UK. jfkirwan@mac.com.

Editorial group: Cochrane Eyes and Vision Group.
Review content assessed as up-to-date: 23 October 2008.


Copyright © 2009 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

ABSTRACT

Background
The outcome of glaucoma surgery can be affected by the rate at which the surgical wound heals. Beta radiation has been proposed as a rapid and simple treatment to slow down the healing response.

Objectives
To assess the effectiveness of beta radiation during glaucoma surgery (trabeculectomy).

Search methods
We searched the Cochrane Central Register of Controlled Trials (CENTRAL) in The Cochrane Library (which includes the Cochrane Eyes and Vision Group Trials Register) (Issue 4 2008), MEDLINE (January 1966 to October 2008) and EMBASE (January 1980 to October 2008). The databases were last searched on 24 October 2008.

Selection criteria
We included randomised controlled trials comparing trabeculectomy with beta radiation to trabeculectomy without beta radiation.

Data collection and analysis
We collected data on surgical failure (intraocular pressure > 21 mmHg), intraocular pressure and adverse effects of glaucoma surgery. We pooled data using a fixed-effect model.

Main results
We found four trials that randomised 551 people to trabeculectomy with beta irradiation versus trabeculectomy alone. Two trials were in Caucasian people (126 people), one trial in black African people (320 people) and one trial in Chinese people (105 people). People who had trabeculectomy with beta irradiation had a lower risk of surgical failure compared to people who had trabeculectomy alone (pooled risk ratio (RR) 0.23 (95% CI 0.14 to 0.40). Beta irradiation was associated with an increased risk of cataract (RR 2.89, 95% CI 1.39 to 6.0).
Authors’ conclusions

Trabeculectomy with beta irradiation has a lower risk of surgical failure compared to trabeculectomy alone. A trial of beta irradiation versus anti-metabolite is warranted.

PLAIN LANGUAGE SUMMARY

Beta radiation in glaucoma surgery

The aim of glaucoma surgery is to lower the pressure in the eye. The outcome of glaucoma surgery can be affected by the rate at which the surgical wound heals. Beta radiation has been proposed as a rapid and simple treatment to slow down the healing response. It is applied during the operation using a radioactive applicator which emits beta rays which have only a very local penetration to a depth of less than one millimetre. The intensity of the emission from the applicator (usually Strontium-90) determines the duration it is applied to the surgical site in order to deliver the required dose of radiation which effectively prevents scar tissue formation.

We found four trials that randomised 551 people to trabeculectomy with beta irradiation versus trabeculectomy alone. People who had trabeculectomy with beta irradiation were less likely to have a high pressure that was too high one year after surgery compared to people who had trabeculectomy alone. However, people who had beta irradiation had an increased risk of cataract after surgery.
<table>
<thead>
<tr>
<th>Outcomes</th>
<th>Illustrative comparative risks* (95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Relative effect (95% CI)</td>
</tr>
<tr>
<td></td>
<td>No of Participants (studies)</td>
</tr>
<tr>
<td></td>
<td>Quality of the evidence (GRADE)</td>
</tr>
<tr>
<td></td>
<td>Comments</td>
</tr>
<tr>
<td><strong>Control</strong></td>
<td></td>
</tr>
<tr>
<td>Low risk population(^1)</td>
<td>RR 0.23 (0.14 to 0.4)</td>
</tr>
<tr>
<td>100 per 1000</td>
<td>561</td>
</tr>
<tr>
<td>23 per 1000 (14 to 40)</td>
<td>moderate(^2)</td>
</tr>
<tr>
<td>High risk population(^1)</td>
<td>RR 1.79 (0.62 to 5.14)</td>
</tr>
<tr>
<td>300 per 1000</td>
<td>423</td>
</tr>
<tr>
<td>69 per 1000 (42 to 120)</td>
<td>low(^3,4)</td>
</tr>
<tr>
<td><strong>Intraocular pressure</strong> (follow-up: 12 months)</td>
<td></td>
</tr>
<tr>
<td>The mean intraocular pressure in the control groups was 13.85 mmHg</td>
<td></td>
</tr>
<tr>
<td>The mean Intraocular pressure in the intervention groups was 0.97 lower (2.56 lower to 0.62 higher)</td>
<td></td>
</tr>
<tr>
<td>123</td>
<td></td>
</tr>
<tr>
<td><strong>Adverse effect: cataract</strong></td>
<td></td>
</tr>
<tr>
<td>Medium risk population</td>
<td>RR 1.79 (0.62 to 5.14)</td>
</tr>
<tr>
<td>50 per 1000</td>
<td>423</td>
</tr>
<tr>
<td>89 per 1000 (31 to 257)</td>
<td>moderate(^5,6)</td>
</tr>
</tbody>
</table>

\(^1\) Low risk population: patients with glaucoma surgery and an intraocular pressure of 15-21 mmHg.

\(^2\) Moderate quality of evidence.

\(^3\) Low risk population: patients with glaucoma surgery and an intraocular pressure of 22-25 mmHg.

\(^4\) Low quality of evidence.

\(^5\) Moderate risk population: patients with glaucoma surgery and an intraocular pressure of 26-30 mmHg.

\(^6\) Moderate quality of evidence.
The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).

<table>
<thead>
<tr>
<th>CI: Confidence interval; RR: Risk ratio;</th>
</tr>
</thead>
</table>

**GRADE Working Group grades of evidence**

**High quality:** Further research is very unlikely to change our confidence in the estimate of effect.

**Moderate quality:** Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.

**Low quality:** Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.

**Very low quality:** We are very uncertain about the estimate.

---

1 Based on control events in included studies. Higher risks of surgical failure seen in black African populations.

2 Majority of evidence from larger high quality study in black African people. However, relative risks for smaller studies in Caucasian and Chinese people were of a similar order but imprecise (pooled relative risk 0.15 (95% CI 0.02 to 1.28)).

3 Data for Caucasian patients only.

4 Two studies contributed data to this outcome, n=123 people. Pooled mean difference was -0.97 (-2.56, 0.62). i.e. beta radiation compatible with a reduction of approximately 2.5mmHg intraocular pressure but also with an increased pressure of less than 1mmHg.

5 Barnes 2000 and Kirwan 2006 had similar estimates of the risk of cataract associated with beta irradiation of approximately 3 to 3.5. In contrast Rehman 2002 had a relative risk reduction of 50%. However, there were small numbers of events (2 cataracts in each group) in Rehman 2002.

6 The pooled analysis had a total of 9 events in the treatment group and 4 in the control group.
BACKGROUND

Beta radiation inhibits wound healing, and has been shown to improve survival of glaucoma filtration surgery in vitro and in vivo (Khaw 1991). Beta radiation causes growth-arrest, primarily due to its effects on P450 (a controller of cell cycling), rather than producing destruction of cells (Constable 1999).

Description of the condition

The term glaucoma defines a group of conditions in which there is characteristic optic neuropathy associated with progressive visual field loss (loss of peripheral and then central vision). Raised intraocular pressure (IOP) is recognised to be one of the principal risk factors for glaucoma (Buhrmann 2000; Hollows 1966; Leske 1995). Glaucoma is the commonest cause of irreversible blindness worldwide, with at least 70 million people affected and over seven million blind from the condition (Quigley 1996). With an ageing world population, the prevalence is likely to increase considerably in the coming years.

Description of the intervention

Lowering IOP has long been established as a means of treating glaucoma, despite a lack of good data for its effectiveness in preventing visual field loss (Rossetti 1993; Vass 2007). What information we do have suggests that surgery is currently the most effective means of lowering IOP (Burr 2004; Migdal 1986, Lichter 2001). Trabeculectomy is the most widely used surgical procedure for glaucoma. In the developed world, surgery is used where other modalities (medical or laser therapy or both) are not sufficiently effective. In poorer countries trabeculectomy may be used as a primary treatment for glaucoma.

The aim of the trabeculectomy operation is to create a fistula (channel) between the anterior chamber and the subconjunctival space to allow controlled release of fluid from the eye. A partial-thickness scleral flap is fashioned at the limbus, with a sclerostomy created under this flap forming a so-called guarded fistula. Fluid from the anterior chamber drains out of the eye through this fistula to the subconjunctival space forming a conjunctival bleb. Fluid in this bleb is thought to be carried away by vessels within the conjunctiva and also by passing through the conjunctival wall. Final IOP may be determined by the size of the bleb, downstream drainage from the conjunctival vessels and the healing response of the eye. The most common cause for failure of trabeculectomy is subconjunctival fibrosis (Hitchings 1983) resulting in occlusion of the fistula with loss of IOP lowering effect.

In elderly white people with glaucoma who have not had prior eye surgery, the success rate of surgery is considered to be in the region of 80%. However, the success rate is lower in certain groups including black people, people with ocular inflammation or neovascularisation, those who have had previous ocular surgery and children (Ritch 1996). It is also apparent that prior topical medical treatment may prejudice the overall success of surgery (Broadway 1994; Lavin 1990). Various agents have been used to reduce the excessive healing that leads to failure of trabeculectomy. The most widely used agents are Mitomycin C and 5-Fluorouracil. Mitomycin C was introduced in 1983 although widespread use did not occur until the mid 1990s (Chen 1983). 5-Fluorouracil was introduced in 1984, after positive reports from a randomised controlled trial (RCT), and was used widely until use of Mitomycin C became widespread (FFSG 1996; Heuer 1984; Singh 2000). Systematic reviews of postoperative 5-Fluorouracil (Wormald 2001) and of intraoperative Mitomycin C (Wilkins 2005) are already published in The Cochrane Library. Although both of these antimetabolites have proven effective clinically they are associated with complications. Both Mitomycin C and 5-Fluorouracil are used in liquid form, delivered by placing microsurgical sponges soaked in the drug directly onto the operative site. Because the antimetabolites are liquids they carry the risk of leakage away from the treatment site. This leakage can lead to extraocular or, more seriously, intraocular toxicity (Franks 1991). Furthermore, the variability of the delivery of the drug between the impregnated sponge and the subconjunctival tissues means that accurate dosimetry has proven difficult. Both treatments have been associated with the development of thin, avascular filtration blebs, and these are in turn associated with an increased risk of sight threatening complications including hypotony (a very soft eye) and endophthalmitis (ocular infection) (Wolner 1991; Yaldo 1993; Zacharia 1993).

One alternative to the use of antimetabolites is beta radiation. Precise control of dose and area of treatment may be easily achieved as it is applied using a Strontium-90 applicator at the completion of surgery. The doses used are typically 750 cGy or 1000 cGy and single application is used without fractionation. Beta radiation was first used for glaucoma surgery in the 1940s (Illiff 1944) and has been used at Moorfields Eye Hospital for many years in the management of paediatric glaucoma. Good results were reported with a non-randomised retrospective study in a cohort of these patients (Miller 1991). Beta radiation may be especially suitable for use in developing countries due to the technical simplicity of application and as no running costs are required.

Why it is important to do this review

Recently, several workers have described the use of beta radiation with trabeculectomy. The overall effectiveness of this mode of therapy is unknown and a systematic review is needed to assess the effects both in people where a high success rate is expected and in those where a lower success rate would be expected.

OBJECTIVES
The aims of this review were to assess the effects of beta radiation with trabeculectomy on surgical failure due to postoperative scarring in people with glaucoma. Mean IOP was an additional primary outcome. The review also aimed to gather evidence on whether beta radiation is associated with increased complications after surgery as compared to standard trabeculectomy.

**METHODS**

**Criteria for considering studies for this review**

**Types of studies**
We included randomised controlled trials of acceptable quality.

**Types of participants**
We included trials in which participants were people with glaucoma undergoing trabeculectomy. All glaucoma diagnosis categories were included. We included people undergoing a first surgical procedure without any perceived risk factors for surgical failure and people who were considered to have a high risk of surgical failure. We did not include people undergoing simultaneous bilateral surgery.

**Types of interventions**
We included trials in which trabeculectomy with beta radiation applied at any dose was compared to trabeculectomy alone, with placebo or with another anti-scarring agent. We excluded trials in which trabeculectomy was combined with cataract extraction.

**Types of outcome measures**

**Primary outcomes**
The primary outcome measures for this review were:
1. the proportion of failed trabeculectomies at 12 months or more after surgery (defined as repeat surgery or uncontrolled IOP more than 20 mmHg with or without additional topical or systemic medications);
2. mean IOP at 12 months or more. Intraocular pressure is used as a primary outcome measure for many clinical trials in glaucoma. The ideal outcome measure is visual function, most commonly expressed in terms of visual field (with allowance for visual acuity). However, the difficulty in determining visual field progression due to the inherently high noise in this psychophysical measure means that trials using this outcome measure need to be performed with large sample sizes and long follow-up time. For practical reasons, IOP was used as a surrogate measurement; the degree of IOP reduction appears to be related to the rate of visual field progression (Gaasterland 2000).

**Secondary outcomes**
Secondary outcome measures included:
3. adverse effects including:
   a. visual loss,
   b. wound leaks: the presence of a positive Seidel test (visible aqueous flow with the tear film stained with fluorescein),
   c. late endophthalmitis - an infection of the globe contents that even with prompt aggressive treatment often results in substantial loss of visual function. 'Late' here implies infection arising from organisms gaining access to the globe through thin walled drainage blebs or frank breaks in the conjunctival epithelium after the immediate postoperative period when infectious agents may have entered the eye during the surgical procedure,
   d. hypotony: the IOP is below five millimetres mercury and/or associated with complications such as macular oedema and sight loss or choroidal detachments,
   e. cataract: the subsequent development of visually significant cataract.
4. outcomes relating to quality of life or patient's perspective of care;
5. data relevant to economic evaluation.

**Search methods for identification of studies**

**Electronic searches**
We searched the Cochrane Central Register of Controlled Trials (CENTRAL) (which contains the Cochrane Eyes and Vision Group Trials Register) (The Cochrane Library, Issue 4, 2008), MEDLINE (January 1960 to October 2008) and EMBASE (January 1980 to October 2008). There were no language or date restrictions in the search for trials. All databases were last searched on 24 October 2008.

See: Appendices for details of search strategies for CENTRAL (Appendix 1), MEDLINE (Appendix 2) and EMBASE (Appendix 3).

**Searching other resources**
We manually searched the Association for Research in Vision and Ophthalmology (ARVO) abstract books from 1990 using a keyword index search for relevant studies. Keywords used were: radiation; beta radiation; strontium. All studies with these words in the permuted index were examined to see if they were relevant. We contacted researchers who are active in the field and manufacturers of the emitter for information on further published or unpublished studies.
Data collection and analysis

Selection of studies
Two authors independently screened the titles and abstracts obtained by the searches and full copies of definitely or potentially relevant studies were obtained. Where the trial had not been fully reported, or was unreported, we attempted to contact the investigators and endeavour to obtain as much relevant data as possible. Details of the trial were not masked during the assessment.

Assessment of risk of bias in included studies
Relevant details about study design were extracted independently by two authors. Risk of bias was assessed using the Cochrane Collaboration's tool for assessing risk of bias which is a domain-based evaluation (Higgins 2008). We contacted study authors for further information on any item graded as unclear.

Data synthesis
For description of dichotomous data such as failure rates, a summary odds ratio was calculated. For IOP, the weighted mean difference was reported. As there were three studies or less to be combined, we used a fixed-effect model. If further trials are included in future updates of this review we will use a random-effects model. There were not enough published studies to investigate potential publication bias nor to conduct sensitivity analyses as planned in the protocol (excluding poorer quality studies).

Subgroup analysis and investigation of heterogeneity
No subgroup analyses were planned in the protocol. The included trials were conducted in different populations (black African, Caucasian and Chinese). There is some evidence that people of African origin have a higher risk of surgical failure (AGIS 2001). In the included trials there was some evidence that the control group risk of failure of surgery was different in different ethnic groups (see Table 1). We therefore did a (posthoc) subgroup analysis by ethnic group.

 RESULTS

Description of studies
See: Characteristics of included studies; Characteristics of excluded studies.

Results of the search
The electronic searches identified 1180 references.

Included studies
See Table 1 and 'Characteristics of included studies' for further details. Four trials were found (Barnes 2000; Lai 1994; Rehman 2002; Kirwan 2006). Two trials (Barnes 2000; Rehman 2002) were performed in Caucasian people, with primary open angle glaucoma with an expected high success rate. Lai 1994 was found in abstract form, which had been performed in Chinese people with open angle glaucoma. The success rate in this trial was also expected to be high, although not as high as for Caucasian people. One trial was performed in black African patients (Kirwan 2006). Two trials used a dosage of 750 cGy (Barnes 2000; Rehman 2002) and two trials used a dosage of 1000 cGy (Kirwan 2006; Lai 1994). A total of 551 people were randomised in these four trials. Follow-up ranged from 12 months (Rehman 2002) to four years (Kirwan 2006).

Excluded studies
See Characteristics of excluded studies for details.

Risk of bias in included studies
See Figure 1 and Figure 2. The trials reported as research papers were of acceptable methodological quality (Barnes 2000; Kirwan 2006; Rehman 2002). In all three trials, sealed envelopes with a randomised number sequence were used for allocation concealment. Examiners determining outcome were unaware of trial allocation. The study published in abstract form has not been subsequently published but we were able to get some information from the trial investigator who reported adequate allocation concealment. Intention-to-treat analysis was not formally reported in any trial. In all trials, only one eye was entered into the trial.
Figure 1. Methodological quality summary: review authors’ judgements about each methodological quality item for each included study.

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Barnes 2000</td>
<td><img src="questionmark" alt="" /></td>
<td>+</td>
<td>?</td>
<td>+</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>Kirwan 2006</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>Lai 1994</td>
<td>?</td>
<td>+</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Rehman 2002</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
</tr>
</tbody>
</table>
Effects of interventions

See: Summary of findings for the main comparison
People who had trabeculectomy with beta irradiation had a lower risk of surgical failure one year after surgery compared to people who had trabeculectomy alone (Analysis 1.1 pooled risk ratio 0.23 (95% confidence interval (CI) 0.14 to 0.40)). The treatment effect appeared to be similar in the different ethnic groups. However the three trials in non African people were smaller and the risk of surgical failure lower in Caucasian people. In the two trials of Caucasian people there were no cases of surgical failure in the treatment group. This analysis, therefore, does not have good power to detect true differences in treatment effect in the different ethnic groups. Only two trials reported mean IOP at the end of the study (Analysis 2.1). People receiving beta irradiation had on average 1 mmHg lower IOP 12 months after surgery. However, this result was not statistically significant and the result is compatible with both lower and higher IOP after surgery (pooled mean difference -0.97 95% CI -2.56 to 0.62).

The most recent study conducted on a South African population was the largest with the greatest power to detect a difference in which the relative risk of failure was reduced by 0.21 (0.11 to 0.40) at one year Kirwan 2006.

The two trials reporting results in Caucasians both had very high success rates. The study from New Zealand, Barnes 2000 showed a small trend for people having beta radiation to have a higher success rate, a lower IOP and a larger drop in IOP. None of these results were significant. The study from Leeds, Rehman 2002 had success rates of 95% and 100% in each arm of the trial for the most generous definition of success and high success rates, even for more stringent definitions. There was no significant difference in success rates between the two arms of the trial for any outcome measure. Neither study had sufficient power to compare adverse effect rates.

The Hong Kong study, Lai 1994 demonstrated a significant difference in success between the two arms of the study. The failure rate was 25% in the control arm and 9% in the treatment arm. Adverse effects were reported in all studies but numbers were low. There was evidence of an increased risk of cataract requiring surgical intervention in the treatment group (Analysis 3.1 pooled risk ratio 2.89 (95% CI 1.39 to 6.00)). Numbers of other complications were too low to comment on (Analysis 3.2; Analysis 3.3), although there was a suggestion that beta radiation augmented trabeculectomy was associated with a small increase in the risk of ocular hypotony (Analysis 3.2).

DISCUSSION

Several points are worthy of comment in considering the data. In the Barnes 2000 study, four participants had only three months follow-up. We were able to obtain the raw data from the investigators. One of those four participants had failed surgery with an IOP 21 mmHg or more at three months. We have counted this patient as a surgical failure at 12 months as well. For the other three patients who had an IOP less than 21 mmHg at three months we cannot make any assumptions about their status at 12 months. The dose used for both the Rehman 2002 and Barnes 2000 studies was 750 cGy, this is less than the dose used in Lai 1994 and cell
Beta radiation for glaucoma surgery (Review)

References

References to studies included in this review

Barnes 2000 {published data only}

Kirwan 2006 {published data only}

Lai 1994 {published data only}

Rehman 2002 {published data only}

References to studies excluded from this review

Tesha 2002 {published data only}
Tesha PE, Rehman SU, Amoaku WMK, Doran RML, Menage MJ, Morrell AJ. Investigation into the use of beta irradiation as an adjunct to trabeculectomy in open angle glaucoma. Congress of the Royal College of Ophthalmologists. 2002.

Additional references

AGIS 2001

Broadway 1994
Broadway DC, Grierson I, O’Brien C, Hitchings RA. Adverse effects of topical antiglaucoma medication regimes:

**AUTHORS’ CONCLUSIONS**

**Implications for practice**

Beta radiation-augmented trabeculectomy reduces the risk of surgical failure compared to standard trabeculectomy. It may be clinically useful but it is unknown how it compares in both effectiveness and safety to other, more widely used antimetabolites. Data on adverse effects are limited. A specific role for beta radiation is unclear and this depends on there being more evidence available to guide practice.

**Implications for research**

There are only four trials of beta radiation for increasing the probability of success in trabeculectomy. Much of the existing evidence for controlling wound healing after trabeculectomy concentrates on liquid antimetabolites. How beta radiation compares to liquid antimetabolites is unknown. Beta radiation may be particularly useful in a developing world setting but this has yet to be evaluated. Outcomes of particular interest are the degree of IOP lowering, success rates in the long term, and adverse effects - particularly cataract. Further trials comparing beta radiation with other antimetabolites would be useful in such a setting but may also be of relevance to richer countries.

**ACKNOWLEDGEMENTS**

We are grateful to the peer reviewers including David Broadway, Catey Bunce and Suzanne Brodney-Folse for comments on this review and to investigators who shared their data with us.

Buhrmann 2000

Burr 2004

Chen 1983

Constable 1999

FFSG 1996

Franks 1991

Gaasterland 2000

Glanville 2006

Heuer 1984

Higgins 2008

Hitchings 1983

Hollows 1966

Iliff 1944

Khaw 1991

Lavin 1990

Leske 1995

Lichter 2001

Migdal 1986

Miller 1991

Quigley 1996

Ritch 1996

Rossetti 1993

Singh 2000

Vass 2007

**Wilkins 2005**


**Wolner 1991**


**Wormald 2001**


**Yaldo 1993**


**Zacharia 1993**


* Indicates the major publication for the study
## Characteristics of included studies  
[ordered by study ID]

**Barnes 2000**

<table>
<thead>
<tr>
<th>Methods</th>
<th>sealed envelopes, randomised number sequence, 3 lost to FU</th>
</tr>
</thead>
<tbody>
<tr>
<td>Participants</td>
<td>Caucasian &gt; 45</td>
</tr>
<tr>
<td>Interventions</td>
<td>trabeculectomy +/- beta radiation</td>
</tr>
<tr>
<td>Outcomes</td>
<td>IOP &lt; 21 = success (+/- medication) mean IOP</td>
</tr>
</tbody>
</table>

### Risk of bias

<table>
<thead>
<tr>
<th>Item</th>
<th>Authors’ judgement</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Adequate sequence generation?</td>
<td>Unclear</td>
<td>“The patients randomly received or did not receive a dose of beta radiation” Page 259, last paragraph</td>
</tr>
<tr>
<td>Blinding? All outcomes</td>
<td>Yes</td>
<td>“There was no record of beta radiation treatment in the patient notes, so at follow up the examining doctor did not know which arm of the study the patient belonged to” Bottom of page 259 top of page 260. We have made the assumption that the patient did not know either although this was not explicitly stated</td>
</tr>
<tr>
<td>Incomplete outcome data addressed? All outcomes</td>
<td>Unclear</td>
<td>“...follow-up periods ranged between 3 and 42 months. Three patients only had 3 months follow-up...” Page 261, first paragraph. However, follow-up times for each treatment group were not given</td>
</tr>
<tr>
<td>Free of selective reporting?</td>
<td>Yes</td>
<td>The main outcome reported in this study was intraocular pressure, as would be expected</td>
</tr>
<tr>
<td>Free of other bias?</td>
<td>Yes</td>
<td></td>
</tr>
</tbody>
</table>

---

*Beta radiation for glaucoma surgery (Review)*  
Copyright © 2009 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
**Kirwan 2006**

<table>
<thead>
<tr>
<th><strong>Methods</strong></th>
<th>opaque sealed envelopes, envelopes opened immediately before administration of treatment or placebo during surgery random number sequence with masking of allocation by outside agency, no exclusions, 30% lost to follow up</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Participants</strong></td>
<td>Africans &gt; 40</td>
</tr>
<tr>
<td><strong>Interventions</strong></td>
<td>trabeculectomy + beta radiation or dummy application</td>
</tr>
<tr>
<td><strong>Outcomes</strong></td>
<td>IOP &lt; 21 without medication</td>
</tr>
<tr>
<td><strong>Notes</strong></td>
<td>Risk of bias assessment made on Kirwan et al. BMJ, doi:10.1136/bmj.38971.395301.7C (published 5 October 2006)</td>
</tr>
</tbody>
</table>

### Risk of bias

<table>
<thead>
<tr>
<th>Item</th>
<th>Authors’ judgement</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Adequate sequence generation?</td>
<td>Yes</td>
<td>“Randomisation was in blocks of 20..” First sentence, page 2.</td>
</tr>
<tr>
<td>Allocation concealment?</td>
<td>Yes</td>
<td>“... with the assigned groups distributed to each centre in opaque, sealed envelopes. Each participant was allocated a trial number on recruitment. The envelope with that number was opened during surgery to determine allocation” Page 2, first paragraph.</td>
</tr>
<tr>
<td>Blinding?</td>
<td>All outcomes</td>
<td>Yes</td>
</tr>
</tbody>
</table>
| Incomplete outcome data addressed? | All outcomes | Yes | “Twenty participants (6%) dropped out of the study after surgery. Some evidence was found that the probability of not being seen was associated with sex (women 10% v men 4%: P = 0.03), blindness in the fellow eye (9% v 3%: P = 0.02), and centre (Bloemfontein 2%, Edendale 9%, Pretoria 3%: P = 0.09; table 1). No strong evidence was found for an association with other variables. A further 68 patients were lost to follow-up before 12 months (36 in the radiation arm). Similar mean numbers of fol-
low-up visits were completed in each of the treatment groups (4.9 radiation group; 4.5 placebo group; P = 0.35). Participants who were followed up showed similar distributions for socio-demographic, ophthalmic, and surgical factors in the treatment arms (table 1).”

From figure 1:
117/156 (75%) in control group followed at 12 months; 115/164 (70%) of radiation group followed at 12 months.

Free of selective reporting?
Yes
All outcomes specified in the protocol were reported in the paper. Jim Kirwan

Free of other bias?
Yes

Lai 1994

Methods
sealed envelopes, randomised number sequence, ? exclusions ? FU

Participants
Hong Kong Chinese > 30

Interventions
trabeculectomy +/- beta radiation

Outcomes
IOP < 21 = success (+/- medication) mean IOP

Notes
published in abstract form only

Risk of bias

<table>
<thead>
<tr>
<th>Item</th>
<th>Authors’ judgement</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Adequate sequence generation?</td>
<td>Unclear</td>
<td>“Patients with primary open angle glaucoma whose pressure was over 21 mmHg on maximum anti-glaucoma medications were assigned randomly to either Group 1: Trabeculectomy, or Group 2) Trabeculectomy + Intraoperative beta irradiation.”</td>
</tr>
<tr>
<td>Allocation concealment?</td>
<td>Yes</td>
<td></td>
</tr>
</tbody>
</table>
Rehman 2002

<table>
<thead>
<tr>
<th>Methods</th>
<th>random number table, no exclusions, no loss to FU</th>
</tr>
</thead>
<tbody>
<tr>
<td>Participants</td>
<td>Caucasian &gt; 40</td>
</tr>
<tr>
<td>Interventions</td>
<td>trabeculectomy +/- beta radiation</td>
</tr>
<tr>
<td>Outcomes</td>
<td>IOP &lt; 21 = success (+/- medication) mean IOP</td>
</tr>
<tr>
<td>Notes</td>
<td>recruitment terminated early due to changes in clinical practice</td>
</tr>
</tbody>
</table>

**Risk of bias**

<table>
<thead>
<tr>
<th>Item</th>
<th>Authors’ judgement</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Adequate sequence generation?</td>
<td>Yes</td>
<td>“A random numbers table was used to assign each eye to either control or beta irradiation group.” Page 303, materials and methods, first paragraph, last sentence.</td>
</tr>
<tr>
<td>Allocation concealment?</td>
<td>Yes</td>
<td>“...with ophthalmologist and patient masked to the assignment.” Page 303, materials and methods, first paragraph, last sentence. Given this statement allocation concealment likely.</td>
</tr>
<tr>
<td>Blinding? All outcomes</td>
<td>Yes</td>
<td>“Patients in the control group received an identical applicator but without an active source (an inactive plaque also designed by Amersham).” Page 303, materials and methods, middle of 3rd paragraph. There is not much information on blinding but given this statement it would be unlikely that patients and outcome assessors would know which had received beta-radiation.</td>
</tr>
<tr>
<td>Incomplete outcome data addressed? All outcomes</td>
<td>Yes</td>
<td>No exclusions and no attrition reported. 61 patients were enrolled into the trial and data on 61 patients reported at 12 months for all outcomes (100% follow-up)</td>
</tr>
<tr>
<td>Free of selective reporting?</td>
<td>Yes</td>
<td>The main outcome reported in this study was intraocular pressure. This is as would be expected and in any case there were no statistically significant differences between the groups with respect to this outcome.</td>
</tr>
</tbody>
</table>
Free of other bias? | Yes | Early termination of patient recruitment was reported because patient recruitment was slow. However, this early termination was not determined by the results of the study.

FU: follow up
IOP: intraocular pressure

**Characteristics of excluded studies** [ordered by study ID]

<table>
<thead>
<tr>
<th>Study</th>
<th>Reason for exclusion</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tesha 2002</td>
<td>Further report of data in Rehman’s study in abstract form</td>
</tr>
</tbody>
</table>
## DATA AND ANALYSES

### Comparison 1. Surgical failure

<table>
<thead>
<tr>
<th>Outcome or subgroup title</th>
<th>No. of studies</th>
<th>No. of participants</th>
<th>Statistical method</th>
<th>Effect size</th>
</tr>
</thead>
<tbody>
<tr>
<td>1 IOP &gt; 21 mmHg 12 months or more after surgery</td>
<td>4</td>
<td>123</td>
<td>RR (Fixed, 95% CI)</td>
<td>0.23 [0.14, 0.40]</td>
</tr>
<tr>
<td>1.1 Black African people</td>
<td>1</td>
<td>1</td>
<td>RR (Fixed, 95% CI)</td>
<td>0.21 [0.11, 0.40]</td>
</tr>
<tr>
<td>1.2 Caucasian people</td>
<td>2</td>
<td>2</td>
<td>RR (Fixed, 95% CI)</td>
<td>0.15 [0.02, 1.28]</td>
</tr>
<tr>
<td>1.3 Chinese people</td>
<td>1</td>
<td>1</td>
<td>RR (Fixed, 95% CI)</td>
<td>0.34 [0.12, 0.96]</td>
</tr>
</tbody>
</table>

### Comparison 2. Intraocular pressure (IOP)

<table>
<thead>
<tr>
<th>Outcome or subgroup title</th>
<th>No. of studies</th>
<th>No. of participants</th>
<th>Statistical method</th>
<th>Effect size</th>
</tr>
</thead>
<tbody>
<tr>
<td>1 Mean IOP 12 months or more after surgery</td>
<td>2</td>
<td>123</td>
<td>Mean Difference (IV, Fixed, 95% CI)</td>
<td>-0.97 [-2.56, 0.62]</td>
</tr>
</tbody>
</table>

### Comparison 3. Adverse effects

<table>
<thead>
<tr>
<th>Outcome or subgroup title</th>
<th>No. of studies</th>
<th>No. of participants</th>
<th>Statistical method</th>
<th>Effect size</th>
</tr>
</thead>
<tbody>
<tr>
<td>1 Cataract</td>
<td>2</td>
<td>362</td>
<td>Risk Ratio (M-H, Fixed, 95% CI)</td>
<td>2.89 [1.39, 6.00]</td>
</tr>
<tr>
<td>2 Hypotony</td>
<td>3</td>
<td>423</td>
<td>Risk Ratio (M-H, Fixed, 95% CI)</td>
<td>1.79 [0.62, 5.14]</td>
</tr>
<tr>
<td>3 Bleb leak</td>
<td>2</td>
<td>123</td>
<td>Odds Ratio (M-H, Fixed, 95% CI)</td>
<td>0.53 [0.12, 2.38]</td>
</tr>
</tbody>
</table>
## Analysis 1.1. Comparison 1 Surgical failure, Outcome 1 IOP > 21 mmHg 12 months or more after surgery.

**Review:** Beta radiation for glaucoma surgery

**Comparison:** 1 Surgical failure

**Outcome:** 1 IOP > 21 mmHg 12 months or more after surgery

<table>
<thead>
<tr>
<th>Study or subgroup</th>
<th>log RR (SE)</th>
<th>RR (Fixed, 95% CI)</th>
<th>Weight</th>
<th>RR (Fixed, 95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1 Black African people</td>
<td>-1.56 (0.33)</td>
<td>0.21 [0.11, 0.40]</td>
<td>67.6%</td>
<td>0.21 [0.11, 0.40]</td>
</tr>
<tr>
<td>Kirwan 2006</td>
<td>-1.56 (0.33)</td>
<td>0.21 [0.11, 0.40]</td>
<td>67.6%</td>
<td>0.21 [0.11, 0.40]</td>
</tr>
<tr>
<td>Subtotal (95% CI)</td>
<td>-1.56 (0.33)</td>
<td>0.21 [0.11, 0.40]</td>
<td>67.6%</td>
<td>0.21 [0.11, 0.40]</td>
</tr>
<tr>
<td>2 Caucasian people</td>
<td>0.60 (1.45)</td>
<td>0.13 [0.01, 2.24]</td>
<td>3.5%</td>
<td>0.13 [0.01, 2.24]</td>
</tr>
<tr>
<td>Barnes 2000</td>
<td>-2.04 (1.45)</td>
<td>0.13 [0.01, 2.24]</td>
<td>3.5%</td>
<td>0.13 [0.01, 2.24]</td>
</tr>
<tr>
<td>Rehman 2002</td>
<td>-1.66 (1.62)</td>
<td>0.19 [0.01, 4.51]</td>
<td>2.8%</td>
<td>0.19 [0.01, 4.51]</td>
</tr>
<tr>
<td>Subtotal (95% CI)</td>
<td>-1.66 (1.62)</td>
<td>0.19 [0.01, 4.51]</td>
<td>6.3%</td>
<td>0.15 [0.02, 1.28]</td>
</tr>
<tr>
<td>3 Chinese people</td>
<td>0.26 (0.53)</td>
<td>0.34 [0.12, 0.96]</td>
<td>26.1%</td>
<td>0.34 [0.12, 0.96]</td>
</tr>
<tr>
<td>Lai 1994</td>
<td>-1.08 (0.53)</td>
<td>0.34 [0.12, 0.96]</td>
<td>26.1%</td>
<td>0.34 [0.12, 0.96]</td>
</tr>
<tr>
<td>Subtotal (95% CI)</td>
<td>-1.08 (0.53)</td>
<td>0.34 [0.12, 0.96]</td>
<td>26.1%</td>
<td>0.34 [0.12, 0.96]</td>
</tr>
<tr>
<td>Total (95% CI)</td>
<td>-1.08 (0.53)</td>
<td>0.34 [0.12, 0.96]</td>
<td>26.1%</td>
<td>0.34 [0.12, 0.96]</td>
</tr>
</tbody>
</table>

Heterogeneity: not applicable

- Test for overall effect: Z = 4.74 (P < 0.00001)
- Test for subgroup differences: Chi² = 0.75, df = 2 (P = 0.69), I² = 0.0%

Heterogeneity: Chi² = 0.03, df = 1 (P = 0.86); I² = 0.0%

- Test for overall effect: Z = 1.73 (P = 0.083)
- Test for overall effect: Z = 2.03 (P = 0.042)

Heterogeneity: Chi² = 0.78, df = 3 (P = 0.85); I² = 0.0%

- Test for overall effect: Z = 5.37 (P < 0.00001)

Heterogeneity: Chi² = 0.75, df = 2 (P = 0.69), I² = 0.0%

- Test for overall effect: Z = 5.37 (P < 0.00001)
Analysis 2.1. Comparison 2 Intraocular pressure (IOP), Outcome 1 Mean IOP 12 months or more after surgery.

Review: Beta radiation for glaucoma surgery
Comparison: 2 Intraocular pressure (IOP)
Outcome: 1 Mean IOP 12 months or more after surgery

<table>
<thead>
<tr>
<th>Study or subgroup</th>
<th>Treatment</th>
<th>Control</th>
<th>Mean Difference</th>
<th>Weight</th>
<th>Mean Difference</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>N</td>
<td>Mean(SD)</td>
<td>N</td>
<td></td>
<td>N</td>
</tr>
<tr>
<td>Barnes 2000</td>
<td>29</td>
<td>12.1 (4.37)</td>
<td>33</td>
<td>13.85 (4.2)</td>
<td>55.2 %</td>
</tr>
<tr>
<td>Rehman 2002</td>
<td>39</td>
<td>13 (4.8)</td>
<td>22</td>
<td>13 (4.4)</td>
<td>44.8 %</td>
</tr>
<tr>
<td>Total (95% CI)</td>
<td>68</td>
<td>55</td>
<td>100.0 %</td>
<td>-0.97 [-2.56, 0.62]</td>
<td></td>
</tr>
</tbody>
</table>

Heterogeneity: Chi^2 = 1.15, df = 1 (P = 0.28); I^2 = 13%
Test for overall effect: Z = 1.19 (P = 0.23)
Test for subgroup differences: Not applicable

Analysis 3.1. Comparison 3 Adverse effects, Outcome 1 Cataract.

Review: Beta radiation for glaucoma surgery
Comparison: 3 Adverse effects
Outcome: 1 Cataract

<table>
<thead>
<tr>
<th>Study or subgroup</th>
<th>Treatment</th>
<th>Control</th>
<th>Risk Ratio</th>
<th>Weight</th>
<th>Risk Ratio</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>n/N</td>
<td>n/N</td>
<td>M-H,Fixed,95% CI</td>
<td></td>
<td>M-H,Fixed,95% CI</td>
</tr>
<tr>
<td>Barnes 2000</td>
<td>7/29</td>
<td>4/33</td>
<td>42.6 %</td>
<td>1.99 [0.65, 6.12]</td>
<td></td>
</tr>
<tr>
<td>Kirwan 2006</td>
<td>18/151</td>
<td>5/149</td>
<td>57.4 %</td>
<td>3.55 [1.35, 9.32]</td>
<td></td>
</tr>
<tr>
<td>Total (95% CI)</td>
<td>180</td>
<td>182</td>
<td>100.0 %</td>
<td>2.89 [1.39, 6.00]</td>
<td></td>
</tr>
</tbody>
</table>

Total events: 25 (Treatment), 9 (Control)
Heterogeneity: Chi^2 = 0.60, df = 1 (P = 0.44); I^2 = 0.0%
Test for overall effect: Z = 2.84 (P = 0.0045)
### Analysis 3.2. Comparison 3 Adverse effects, Outcome 2 Hypotony.

**Review:** Beta radiation for glaucoma surgery

**Comparison:** 3 Adverse effects

**Outcome:** 2 Hypotony

<table>
<thead>
<tr>
<th>Study or subgroup</th>
<th>Treatment n/N</th>
<th>Control n/N</th>
<th>Risk Ratio M-H,Fixed,95% CI</th>
<th>Weight</th>
<th>Risk Ratio M-H,Fixed,95% CI</th>
</tr>
</thead>
<tbody>
<tr>
<td>Barnes 2000</td>
<td>1/29</td>
<td>0/33</td>
<td>9.3% 3.40 [0.14, 80.36]</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Kirwan 2006</td>
<td>6/151</td>
<td>2/149</td>
<td>40.0% 2.96 [0.61, 14.43]</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Rehman 2002</td>
<td>2/39</td>
<td>2/22</td>
<td>50.7% 0.56 [0.09, 3.73]</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Total (95% CI)</strong></td>
<td><strong>219</strong></td>
<td><strong>204</strong></td>
<td><strong>100.0% 1.79 [0.62, 5.14]</strong></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Total events: 9 (Treatment), 4 (Control)

Heterogeneity: Chi² = 1.98, df = 2 (P = 0.37); I² =0.0%

Test for overall effect: Z = 1.07 (P = 0.28)

### Analysis 3.3. Comparison 3 Adverse effects, Outcome 3 Bleb leak.

**Review:** Beta radiation for glaucoma surgery

**Comparison:** 3 Adverse effects

**Outcome:** 3 Bleb leak

<table>
<thead>
<tr>
<th>Study or subgroup</th>
<th>Treatment n/N</th>
<th>Control n/N</th>
<th>Odds Ratio M-H,Fixed,95% CI</th>
<th>Weight</th>
<th>Odds Ratio M-H,Fixed,95% CI</th>
</tr>
</thead>
<tbody>
<tr>
<td>Barnes 2000</td>
<td>0/29</td>
<td>2/33</td>
<td>49.4% 0.21 [0.01, 4.64]</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Rehman 2002</td>
<td>3/39</td>
<td>2/22</td>
<td>50.6% 0.83 [0.13, 5.41]</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Total (95% CI)</strong></td>
<td><strong>68</strong></td>
<td><strong>55</strong></td>
<td><strong>100.0% 0.53 [0.12, 2.38]</strong></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Total events: 3 (Treatment), 4 (Control)

Heterogeneity: Chi² = 0.56, df = 1 (P = 0.45); I² =0.0%

Test for overall effect: Z = 0.83 (P = 0.40)
### Additional Tables

Table 1. Summary of trial characteristics

<table>
<thead>
<tr>
<th>Study</th>
<th>Ethnic group</th>
<th>Dose</th>
<th>N treatment group</th>
<th>N control group</th>
<th>Surgical failure at 12 months in control group</th>
</tr>
</thead>
<tbody>
<tr>
<td>Barnes 2000</td>
<td>Caucasian</td>
<td>750 cGy</td>
<td>31</td>
<td>34</td>
<td>12%</td>
</tr>
<tr>
<td>Kirwan 2006</td>
<td>Black African</td>
<td>1000 cGy</td>
<td>164</td>
<td>156</td>
<td>30%</td>
</tr>
<tr>
<td>Lai 1994</td>
<td>Chinese</td>
<td>1000 cGy</td>
<td>46</td>
<td>59</td>
<td>26%</td>
</tr>
<tr>
<td>Rehman 2002</td>
<td>Caucasian</td>
<td>750 cGy</td>
<td>39</td>
<td>22</td>
<td>14%</td>
</tr>
</tbody>
</table>

### Appendices

**Appendix 1. CENTRAL search strategy**

#1 MeSH descriptor Glaucoma
#2 MeSH descriptor Filtering Surgery
#3 (glaucoma* or filter* or filtrat*) near (surg*)
#4 MeSH descriptor Trabeculectomy
#5 trabeculectom*
#6 (#1 OR #2 OR #3 OR #4 OR #5)
#7 MeSH descriptor Beta Rays
#8 MeSH descriptor Radiation
#9 MeSH descriptor Strontium
#10 MeSH descriptor Brachytherapy
#11 radiat* or irradat*
#12 strontium or SR 90
#13 beta-rad* or beta irrad*
#14 (#7 OR #8 OR #9 OR #10 OR #11 OR #12 OR #13)
#15 (#6 AND #14)

**Appendix 2. MEDLINE search strategy**

1. randomized controlled trial.pt.
2. (randomized or randomised).ab,ti.
3. placebo.ab,ti.
4. dt.fs.
5. randomly.ab,ti.
6. trial.ab,ti.
7. groups.ab,ti.
8. or/1-7
9. exp animals/
10. exp humans/
11. 9 not (9 and 10)
The search filter for trials at the beginning of the MEDLINE strategy is from the published paper by Glanville et al (Glanville 2006).

**Appendix 3. EMBASE search strategy**

1. exp randomized controlled trial/
2. exp randomization/
3. exp double blind procedure/
4. exp single blind procedure/
5. random$.tw.
6. or/1-5
7. (animal or animal experiment).sh.
8. human.sh.
9. 7 and 8
10. 7 not 9
11. 6 not 10
12. exp clinical trial/
14. ((singl$ or doubl$ or trebl$ or tripl$) adj3 (blind$ or mask$)).tw.
15. exp placebo/
16. placebo$tw.
17. random$.tw.
18. exp experimental design/
19. exp crossover procedure/
20. exp control group/
21. exp latin square design/
22. or/12-21
23. 22 not 10
24. 23 not 11
25. exp comparative study/
26. exp evaluation/
27. exp prospective study/
28. (control$ or prospectiv$ or volunteer$).tw.
29. or/25-28
30. 29 not 10
31. 30 not (11 or 23)
32. 11 or 24 or 31
33. exp glaucoma/
34. exp glaucoma surgery/
35. ((glaucoma$ or filter$ or filtrat$) adj3 surg$).tw.
36. exp trabeculectomy/
37. trabeculectom$.tw.
38. or/33-37
39. exp beta radiation/
40. exp radiation/
41. exp irradiation/
42. exp strontium 90/
43. exp brachytherapy/
44. (radiat$ or irradiat$).tw.
45. (strontium$ or SR 90).tw.
46. (beta-radiat$ or beta-irradiat$).tw.
47. or/39-46
48. 38 and 47
49. 32 and 48

HISTORY
Protocol first published: Issue 1, 2002
Review first published: Issue 2, 2009

<table>
<thead>
<tr>
<th>Date</th>
<th>Event</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>17 March 2008</td>
<td>Amended</td>
<td>Converted to new review format.</td>
</tr>
</tbody>
</table>

CONTRIBUTIONS OF AUTHORS
JK wrote the protocol and assessed studies for inclusion, assessed studies for risk of bias, analysed the results and wrote the text of the review. CR assessed studies for inclusion and risk of bias and helped draft the review. JE assessed studies for risk of bias, extracted and entered data, did the summary of findings table and edited the text of the review.

DECLARATIONS OF INTEREST
One of the review authors (JFK) has conducted an RCT into the effects of beta radiation on augmenting the success of glaucoma surgery in Africans in South Africa.
**SOURCES OF SUPPORT**

**Internal sources**

- Institute of Ophthalmology, UK.

**External sources**

- No sources of support supplied

**DIFFERENCES BETWEEN PROTOCOL AND REVIEW**

Analysis by ethnic group conducted in the review but not specified in the protocol.

**INDEX TERMS**

**Medical Subject Headings (MeSH)**

- Trabeculectomy [methods]; Beta Particles [adverse effects; *therapeutic use]; Cataract [etiology]; Combined Modality Therapy [methods]; Glaucoma [*surgery]; Randomized Controlled Trials as Topic; Treatment Outcome; Wound Healing [*radiation effects*]

**MeSH check words**

Humans